A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (> 12 Yrs) Hispanic Subjects With Asthma.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Budesonide (Primary) ; Budesonide/formoterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 01 Sep 2011 Results published in the Annals of Allergy, Asthma and Immunology.
- 18 May 2011 Results pertaining to secondary endpoints were presented at the 107th International Conference of the American Thoracic Society.
- 22 Dec 2009 Results were presented at the 2009 Annual Meeting of the American College of Allergy, Asthma and Immunology.